SBFM Key Statistics, Chart & Performance
The current stock price of SBFM is 1.39 USD. In the past month the price decreased by -24.46%. In the past year, price decreased by -51.4%.
SBFM Latest News, Press Relases and Analysis
SBFM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.53 | 409.49B | ||
| AMGN | AMGEN INC | 15.6 | 183.64B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 157.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.76 | 110.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.49 | 83.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 842.75 | 56.34B | ||
| INSM | INSMED INC | N/A | 44.18B | ||
| NTRA | NATERA INC | N/A | 32.46B | ||
| BIIB | BIOGEN INC | 10.87 | 26.68B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.41 | 21.97B | ||
| INCY | INCYTE CORP | 16.44 | 20.61B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.15B |
Related stock screener links
About SBFM
Company Profile
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Fort Lauderdale, Florida and currently employs 52 full-time employees. The company went IPO on 2008-08-15. The firm has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The firm operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The firm operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Company Info
SUNSHINE BIOPHARMA INC
333 Las Olas Way, Cu4 Suite 433
FORT LAUDERDALE FLORIDA US
Employees: 52
Phone: 19543300684
SUNSHINE BIOPHARMA INC / SBFM FAQ
Can you describe the business of SUNSHINE BIOPHARMA INC?
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Fort Lauderdale, Florida and currently employs 52 full-time employees. The company went IPO on 2008-08-15. The firm has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The firm operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The firm operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
What is the current price of SBFM stock?
The current stock price of SBFM is 1.39 USD.
Does SUNSHINE BIOPHARMA INC pay dividends?
SBFM does not pay a dividend.
What is the ChartMill technical and fundamental rating of SBFM stock?
SBFM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists SBFM stock?
SBFM stock is listed on the Nasdaq exchange.
What sector and industry does SUNSHINE BIOPHARMA INC belong to?
SUNSHINE BIOPHARMA INC (SBFM) operates in the Health Care sector and the Biotechnology industry.
Should I buy SBFM stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SBFM.
SBFM Technical Analysis
SBFM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SBFM. While SBFM seems to be doing ok healthwise, there are quite some concerns on its profitability.
SBFM Financial Highlights
Over the last trailing twelve months SBFM reported a non-GAAP Earnings per Share(EPS) of -51.88. The EPS increased by 60.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.73% | ||
| ROE | -24.55% | ||
| Debt/Equity | 0 |
SBFM Forecast & Estimates
7 analysts have analysed SBFM and the average price target is 7.14 USD. This implies a price increase of 413.67% is expected in the next year compared to the current price of 1.39.
For the next year, analysts expect an EPS growth of 98.37% and a revenue growth 9.61% for SBFM